Maharashtra Food and Drugs Administration (FDA) has detected 45 not-of-standard drugs in August, 17 in July and 11 during the inspections conducted in September. In 2010 so far, Maharashtra FDA has found highest number of not-of-standard drugs in August. As usual, in the list of August also, manufacturers from tax-free state of Himachal Pradesh account for the major share.

Well-known drug manufacturer, Glenmark Pharmaceuticals also figure in the list in August. Other highlights of Maha FDA's not-of-standard drugs' list were Endolabs, Perennial Medicare and Morepen Labs that were listed in July and August also. Two samples of Endolabs were found not complying with the standards in July and two samples each of Celebrity Biopharma and Park Pharma were found in August.

Out of 45 such drug samples found in August, 16 were from Himachal Pradesh; one each from Andhra Pradesh, Chandigarh, Daman, Goa, Punjab & Uttar Pradesh; two each from Gujarat and Tamil Nadu; four each from Madhya Pradesh and Uttaranchal; and, ten from Maharashtra.

In July, out of the list 17, two each belonged to manufacturers from Chandigarh, Rajasthan, Maharashtra & Uttaranchal, one from Gujarat, one from Germany, three each from Himachal Pradesh and Madhya Pradesh.  

Likewise in the September list, 11 of the not-of-standard drugs, one each is from Punjab, Bihar, Daman & Goa; two from Maharashtra and five from Himachal Pradesh.

During August, apart from Glenmark Pharmaceuticals, companies like Acme Formulation, Arion Healthcare, Biddle Sawyer, D M Pharma, Hetro Labs, Laborate Pharma, Mission Laboratories, Morepen Laboratories, Perennial Medicare, Valence Healthcare, Zee Laboratories, two drugs each from Celebrity Biopharma and Park Pharmaceutical from Himachal Pradesh; Hetro Drugs from Andhra Pradesh; Orison Pharmaceuticals from Chandigarh; Anchor Pharma from Daman; Zurich Healthcare from Delhi; Centaur Pharmaceuticals from Goa; Disha Surgicals from Uttar Pradesh; RPG Life Sciences and Suxes Healthcare from Gujarat; Danish Laboratories, Endolabs, MCW Healthcare, Medic Remedies, Modern Sales Corporation, Surgiview and T M Thakore Pharmaceuticals from Madhya Pradesh; Unijules Life Sciences, Ciron Drugs & Pharmaceuticals, Gelnova Laboratories, TTC, Karnataka Antibiotics & Pharmaceuticals, Shalina Laboratories, Techno Economic Services and US Pharma from Maharashtra; Akums Drugs & Pharmaceuticals, Endolabs Healthcare, Regent Ajanta Biotech and Shreya Life Science from Uttaranchal were listed for non-complying drugs in market.

Among 17 not-of-standard drugs found in July, manufacturers lnamely  Brawn Laboratories and Orison Pharmaceuticals were from Chandigarh; Bharat Parenterals from Gujarat; Morepen Laboratories, Perennial Medicare and Ratchet Laboratories from Himachal Pradesh; two samples of Endolabs and Parkbenz Laboratory from Madhya Pradesh; Jain Surgicals and Medicamen Biotech from Rajasthan; Arco Pharma, Thechno Economic Services from Maharashtra and Shince Healthcare, Taurus Parenterals and Zorex Remedies were from Uttaranchal.

During the inspection conducted in September, 11 not of standard drugs were found and manufacturers were Concept Pharmaceuticals and Excel Pharmaceuticals from Maharashtra; Hindustan Pharmaceuticals from Bihar; Macleodes Pharmaceuticals from Daman; FDC from Goa; Avenue Remedies, Brooks Laboratories, Magma Allianz Laboratories, Nirma Limited and Vapi Care Pharma from Himachal Pradesh and Adison Pharmaceuticals from Punjab.

The state FDA routinely picks up random samples of drugs from chemists and druggists and send for testing. The department will soon issue show cause notices to these companies.